Imane Chaib

1.5k total citations
39 papers, 719 citations indexed

About

Imane Chaib is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Imane Chaib has authored 39 papers receiving a total of 719 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 23 papers in Molecular Biology and 21 papers in Oncology. Recurrent topics in Imane Chaib's work include Lung Cancer Treatments and Mutations (21 papers), RNA modifications and cancer (9 papers) and DNA Repair Mechanisms (5 papers). Imane Chaib is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), RNA modifications and cancer (9 papers) and DNA Repair Mechanisms (5 papers). Imane Chaib collaborates with scholars based in Spain, Italy and China. Imane Chaib's co-authors include Rafael Rosell, Niki Karachaliou, Miquel Tarón, Miguel Ángel Molina‐Vila, Laia Perez‐Roca, Pedro Méndez, José Javier Sánchez, Marcin Skrzypski, Ewa Jassem and Rafael Rosell and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Imane Chaib

37 papers receiving 708 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Imane Chaib Spain 14 428 358 309 199 79 39 719
Shinsuke Hashida Japan 12 382 0.9× 345 1.0× 332 1.1× 225 1.1× 56 0.7× 30 719
Muaiad Kittaneh United States 16 294 0.7× 312 0.9× 447 1.4× 149 0.7× 65 0.8× 40 739
Kentaro Iwanaga Japan 14 489 1.1× 396 1.1× 373 1.2× 241 1.2× 70 0.9× 24 864
Maria Trypaki Greece 14 366 0.9× 438 1.2× 517 1.7× 319 1.6× 118 1.5× 26 869
Jean Powers Canada 9 420 1.0× 265 0.7× 330 1.1× 209 1.1× 53 0.7× 12 748
Liwen Xiong China 17 316 0.7× 476 1.3× 310 1.0× 221 1.1× 62 0.8× 58 808
Hideki Terai Japan 15 480 1.1× 358 1.0× 297 1.0× 199 1.0× 45 0.6× 41 778
Silvia Paola Corona Italy 13 230 0.5× 357 1.0× 391 1.3× 152 0.8× 54 0.7× 43 689
Songwen Zhou China 17 425 1.0× 280 0.8× 236 0.8× 291 1.5× 68 0.9× 39 724
Inés López Spain 10 396 0.9× 198 0.6× 280 0.9× 258 1.3× 46 0.6× 18 664

Countries citing papers authored by Imane Chaib

Since Specialization
Citations

This map shows the geographic impact of Imane Chaib's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Imane Chaib with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Imane Chaib more than expected).

Fields of papers citing papers by Imane Chaib

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Imane Chaib. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Imane Chaib. The network helps show where Imane Chaib may publish in the future.

Co-authorship network of co-authors of Imane Chaib

This figure shows the co-authorship network connecting the top 25 collaborators of Imane Chaib. A scholar is included among the top collaborators of Imane Chaib based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Imane Chaib. Imane Chaib is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cai, Xueting, Sainan Wang, Miguel Ángel Molina‐Vila, et al.. (2021). Dihydroartemisinin overcomes the resistance to osimertinib in EGFR-mutant non-small-cell lung cancer. Pharmacological Research. 170. 105701–105701. 28 indexed citations
2.
Rosell, Rafael, et al.. (2021). KRAS inhibitors, approved. Nature Cancer. 2(12). 1254–1256. 14 indexed citations
3.
Attili, Ilaria, Laura Bonanno, Niki Karachaliou, et al.. (2020). SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer. Translational Lung Cancer Research. 9(5). 1810–1821. 11 indexed citations
4.
Karachaliou, Niki, Óscar Arrieta, Ana Giménez‐Capitán, et al.. (2020). BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib. JTO Clinical and Research Reports. 2(3). 100113–100113. 9 indexed citations
5.
Ito, Masaoki, Jordi Codony‐Servat, Ana Giménez‐Capitán, et al.. (2020). Src-Homology 2 Domain-Containing Phosphatase 2 in Resected EGFR Mutation-Positive Lung Adenocarcinoma. JTO Clinical and Research Reports. 1(4). 100084–100084. 2 indexed citations
6.
Santarpía, Mariacarmela, Jessica Menis, Imane Chaib, María González Cao, & Rafael Rosell. (2019). Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer. Expert Review of Clinical Pharmacology. 12(9). 831–840. 12 indexed citations
7.
Chaib, Imane, Xueting Cai, David Lligé, et al.. (2019). Osimertinib and dihydroartemisinin: a novel drug combination targeting head and neck squamous cell carcinoma. Annals of Translational Medicine. 7(22). 651–651. 14 indexed citations
8.
Codony‐Servat, Jordi, Carles Codony, Santiago Viteri, et al.. (2019). Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models. Annals of Oncology. 30. v10–v11. 2 indexed citations
9.
Codony‐Servat, Jordi, Santiago Viteri, Carles Codony, et al.. (2019). Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines. Translational Lung Cancer Research. 8(4). 340–351. 14 indexed citations
10.
Karachaliou, Niki, Jillian Wilhelmina Paulina Bracht, Ana Drozdowskyj, et al.. (2018). Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(2). 304–310. 13 indexed citations
11.
Karachaliou, Niki, Andrés F. Cardona, Jillian Wilhelmina Paulina Bracht, et al.. (2018). Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC). EBioMedicine. 39. 207–214. 35 indexed citations
12.
Karachaliou, Niki, Martina I. Lefterova, Imane Chaib, et al.. (2018). Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA). Annals of Oncology. 29. viii671–viii671. 1 indexed citations
13.
Rosell, Rafael, Imane Chaib, Niki Karachaliou, et al.. (2017). OA10.03 YAP-NOTCH and STAT3 Signaling Rebound as a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer. Journal of Thoracic Oncology. 12(1). S281–S282. 1 indexed citations
14.
Verlicchi, Alberto, Niki Karachaliou, Chiara Lazzari, et al.. (2017). P3.01-038 STAT3 and Src-YAP1 Inhibition Results in Greater Necitumumab Sensitivity in Lung Squamous Cell Carcinoma. Journal of Thoracic Oncology. 12(1). S1143–S1143.
15.
Karachaliou, Niki, Imane Chaib, Sara Pilotto, et al.. (2016). 76P An innovative co-targeting of signal transducer and activator of transcription 3 (STAT3) and Src-YAP pathways in EGFR mutant non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 11(4). S87–S88. 1 indexed citations
16.
Verlicchi, Alberto, Niki Karachaliou, Chiara Lazzari, et al.. (2016). 72P Differential expression profile of lung squamous cell carcinoma (LSCC) cell lines as a mean to predict drug interaction effects. Journal of Thoracic Oncology. 11(4). S85–S86. 1 indexed citations
17.
Bover, Isabel, Christian Rolfo, Eloísa Jantus‐Lewintre, et al.. (2011). Fifth Educational Symposium of the Spanish Lung Cancer Group: Report on the Molecular Biology Workshop. Lung Cancer. 74(3). 535–543.
18.
Skrzypski, Marcin, Ewa Jassem, Miquel Tarón, et al.. (2008). Three-Gene Expression Signature Predicts Survival in Early-Stage Squamous Cell Carcinoma of the Lung. Clinical Cancer Research. 14(15). 4794–4799. 84 indexed citations
19.
Rosell, R., Nerea Martı́nez, Imane Chaib, et al.. (2007). Expression of XPG mRNA and protein as potential biomarker of response to trabectedin in sarcoma patients. Molecular Cancer Therapeutics. 6. 2 indexed citations
20.
Rosell, Rafael, Marcin Skrzypski, Ewa Jassem, et al.. (2007). BRCA1: A Novel Prognostic Factor in Resected Non-Small-Cell Lung Cancer. PLoS ONE. 2(11). e1129–e1129. 167 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shinsuke Hashida Breakdown of academic impact, for papers by Muaiad Kittaneh Breakdown of academic impact, for papers by Kentaro Iwanaga Breakdown of academic impact, for papers by Maria Trypaki Breakdown of academic impact, for papers by Jean Powers Breakdown of academic impact, for papers by Liwen Xiong Breakdown of academic impact, for papers by Hideki Terai Breakdown of academic impact, for papers by Silvia Paola Corona Breakdown of academic impact, for papers by Songwen Zhou Breakdown of academic impact, for papers by Inés López
Rankless by CCL
2026